Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neurocrine Biosciences (NBIX) Finished Goods (2017 - 2025)

Neurocrine Biosciences (NBIX) has disclosed Finished Goods for 7 consecutive years, with $13.6 million as the latest value for Q1 2025.

  • For the quarter ending Q1 2025, Finished Goods rose 81.33% year-over-year to $13.6 million, compared with a TTM value of $13.6 million through Mar 2025, up 81.33%, and an annual FY2024 reading of $12.8 million, up 4.07% over the prior year.
  • Finished Goods was $13.6 million for Q1 2025 at Neurocrine Biosciences, up from $12.8 million in the prior quarter.
  • Across five years, Finished Goods topped out at $13.6 million in Q1 2025 and bottomed at $7.5 million in Q1 2024.
  • Average Finished Goods over 3 years is $11.4 million, with a median of $11.9 million recorded in 2023.
  • The sharpest move saw Finished Goods increased 4.07% in 2024, then skyrocketed 81.33% in 2025.
  • Year by year, Finished Goods stood at $12.3 million in 2023, then increased by 4.07% to $12.8 million in 2024, then grew by 6.25% to $13.6 million in 2025.
  • Business Quant data shows Finished Goods for NBIX at $13.6 million in Q1 2025, $12.8 million in Q4 2024, and $11.5 million in Q3 2024.